Sociedad Americana de Hirudoterapia

Transcriptomic profiling and the first spatial expression analysis of candidate genes in the salivary gland of the East Asian medicinal leech, Hirudo nipponia

Transcriptomics study published in Dev Comp Immunol (2023)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genómica y proteómicaFarmacología salivalKim JH et al. · Developmental and comparative immunology, 2023

Abstract

Hirudo nipponia, a blood-sucking leech native to East Asia, possesses a rich repertoire of active ingredients in its saliva, showcasing significant medical potential due to its anticoagulant, anti-inflammatory, and antibacterial effects against human diseases. Despite previous studies on the transcriptomic and proteomic characteristics of leech saliva, which have identified medicinal compounds, our knowledge of tissue-specific transcriptomes and their spatial expression patterns remains incomplete. In this study, we conducted an extensive transcriptomic profiling of the salivary gland tissue in H. nipponia based on de novo assemblies of tissue-specific transcriptomes from the salivary gland, teeth, and general head region. Through gene ontology (GO) analysis and hierarchical clustering, we discovered a novel set of anti-coagulant factors-i.e., Hni-Antistasin, Hni-Ghilanten, Hni-Bdellin, Hni-Hirudin-as well as a previously unrecognized immune-related gene, Hni-GLIPR1 and uncharacterized salivary gland specific transcripts. By employing in situ hybridization, we provided the first visualization of gene expression sites within the salivary gland of H. nipponia. Our findings expand on our understanding of transcripts specifically expressed in the salivary gland of blood-sucking leeches, offering valuable resources for the exploration of previously unidentified substances with medicinal applications.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsGene Expression ProfilingHirudo medicinalisLeechesMembrane ProteinsNeoplasm ProteinsNerve Tissue ProteinsProteomicsSalivary Glands

Resumen

Tissue-specific transcriptome of Hirudo nipponia salivary gland identified novel anticoagulant factors (Hni-Antistasin, Hni-Ghilanten, Hni-Bdellin, Hni-Hirudin) and immune-related Hni-GLIPR1 with in situ hybridization spatial mapping.

Por qué esto importa para la hirudoterapia

This study performed de novo transcriptomic profiling of Hirudo nipponia salivary gland, teeth, and head tissues, identifying a novel set of anticoagulant candidates (Hni-Antistasin, Hni-Ghilanten, Hni-Bdellin, Hni-Hirudin), an immune-related gene (Hni-GLIPR1), and uncharacterized salivary-gland-specific transcripts, with in-situ hybridization localizing expression sites. For ASH, this is relevant as a tissue-resolved transcriptomic resource expanding the known candidate bioactive repertoire of a medicinal leech used in East Asia, potentially guiding discovery of new secretome-derived therapeutics. Honest caveat: the study is descriptive molecular biology; no functional bioassays, protein purification, or clinical data are presented, and the anticoagulant activity of the named candidates is inferred from homology rather than directly demonstrated here.

Citación

Transcriptomic profiling and the first spatial expression analysis of candidate genes in the salivary gland of the East Asian medicinal leech, Hirudo nipponia.

Kim JH et al. · Developmental and comparative immunology, 2023

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.